Coherus and Superior Biologics Announce National

First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of...

Related Keywords

Canada ,United States ,Hidradenitis Suppurativa ,Denny Lanfear ,Coherus Biosciences ,Peter Fricke ,John Brandt ,Marek Ciszewski ,Robert Cappa ,Exchange Commission On ,Nasdaq ,Utilization Review Accreditation Commission ,Rokk Solutions ,Exchange Commission ,Accreditation Commission For Healthcare ,Coherus Biosciences Inc ,Biologics Inc ,Superior Biologics ,Coheru Chairman ,Chief Executive ,Idiopathic Arthritis ,Full Prescribing ,Full Prescribing Information ,Boxed Warning ,Biologics License Application ,Joint Commission ,Accreditation Commission ,Private Securities Litigation Reform Act ,Coheru Quarterly Report ,Contact Information ,Biologics Contact ,Nasdaq Chrs ,Nc ,Yusimry ,Coherus ,Humira ,Adalimumab ,